- Home
- CBIO vs CLPT Comparison
CBIO vs CLPT Comparison
Compare CBIO & CLPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- CLPT
- Stock Information
- Founded
- CBIO 2003
- CLPT 1998
- Country
- CBIO United States
- CLPT United States
- Employees
- CBIO N/A
- CLPT N/A
- Industry
- CBIO
- CLPT Medical/Dental Instruments
- Sector
- CBIO
- CLPT Health Care
- Exchange
- CBIO Nasdaq
- CLPT Nasdaq
- Market Cap
- CBIO 308.0M
- CLPT 317.4M
- IPO Year
- CBIO N/A
- CLPT N/A
- Fundamental
- Price
- CBIO $14.29
- CLPT $10.49
- Analyst Decision
- CBIO Strong Buy
- CLPT Strong Buy
- Analyst Count
- CBIO 5
- CLPT 3
- Target Price
- CBIO $25.60
- CLPT $27.67
- AVG Volume (30 Days)
- CBIO 98.3K
- CLPT 375.5K
- Earning Date
- CBIO 07-31-2025
- CLPT 08-12-2025
- Dividend Yield
- CBIO N/A
- CLPT N/A
- EPS Growth
- CBIO N/A
- CLPT N/A
- EPS
- CBIO N/A
- CLPT N/A
- Revenue
- CBIO N/A
- CLPT $33,593,000.00
- Revenue This Year
- CBIO N/A
- CLPT $22.34
- Revenue Next Year
- CBIO N/A
- CLPT $25.50
- P/E Ratio
- CBIO N/A
- CLPT N/A
- Revenue Growth
- CBIO N/A
- CLPT 19.68
- 52 Week Low
- CBIO $10.83
- CLPT $9.76
- 52 Week High
- CBIO $21.40
- CLPT $19.22
- Technical
- Relative Strength Index (RSI)
- CBIO 52.92
- CLPT 44.46
- Support Level
- CBIO $13.50
- CLPT $10.42
- Resistance Level
- CBIO $16.00
- CLPT $10.88
- Average True Range (ATR)
- CBIO 0.79
- CLPT 0.52
- MACD
- CBIO 0.16
- CLPT -0.01
- Stochastic Oscillator
- CBIO 39.68
- CLPT 22.75
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.